Acumen pharmaceuticals presents first comprehensive clinical and biomarker data for sabirnetug (acu193) at american academy of neurology 2024 annual meeting

Charlottesville, va., april 16, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), will present the comprehensive clinical and biomarker results from its positive phase 1 intercept-ad study of sabirnetug (acu193) in early ad during an emerging science session at the american academy of neurology (aan) 2024 annual meeting in denver on april 16, 2024. the results build upon acumen's prior presentations at the ad/pd™ 2024 annual meeting and positive topline data first announced in july 2023 and will be presented together for the first time with expanded analysis.
ABOS Ratings Summary
ABOS Quant Ranking